PMDA
- Application: Kyprolis
- Local brand name: Kyprolis
- Status: approved
🇯🇵 Drug: Carfilzomib + Lenalidomide + Dexamethasone in Japan
Drug: Carfilzomib + Lenalidomide + Dexamethasone (Drug: Carfilzomib + Lenalidomide + Dexamethasone) regulatory status in Japan.
Marketing authorisation
Drug: Carfilzomib + Lenalidomide + Dexamethasone in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in Japan
Frequently asked questions
Is Drug: Carfilzomib + Lenalidomide + Dexamethasone approved in Japan?
Yes. PMDA has authorised it.
Who is the marketing authorisation holder for Drug: Carfilzomib + Lenalidomide + Dexamethasone in Japan?
Amgen is the originator. The local marketing authorisation holder may differ — check the official source linked above.